-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
Study #2015-0604
A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Study Status
Closed
Treatment Agent
Principal Investigator
Jorge Cortes
Description
You are being asked to participate in this study because you have acute myeloid leukemia (AML) that is either relapsed (has come back) or refractory (has not responded to treatment). The goal of this clinical research study is to compare the effects of the study drug ASP2215 to those of standard-of-care chemotherapies in patients with AML with mutations in the FLT3 gene. The safety of these drugs will also be compared.
General Information
Treatment Location: N/A
Sponsor: N/A
Study Status
IRB Review and Approval Date: 05/27/2016
Recruitment Status: Closed
Projected Accrual: N/A
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Phase III
Physician name:
Jorge Cortes
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789